BioInvent International AB (publ) (BINV.ST)

Compare

28.30

-0.15

(-0.53%)

As of 11:36:04 AM GMT+2. Market Open.

BioInvent to Participate in Upcoming Investor Conferences

LUND, SE / ACCESS Newswire / April 1, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire 2 days ago

BOVNF
Notice to Annual General Meeting in BioInvent International AB

LUND, SE / ACCESS Newswire / March 25, 2025 /BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 ...

ACCESS Newswire 9 days ago

BOVNF
BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire 13 days ago

BOVNF
BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire 14 days ago

BOVNF
BioInvent International AB: Year-End Report January 1 - December 31, 2024

LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials ...

ACCESS Newswire last month

BOVNF
Invitation to Presentation of BioInvent's Year-end Report 2024

LUND, SE / ACCESS Newswire / February 25, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2024 on February 27 at 4:00 pm CET. The report will ...

ACCESS Newswire last month

BOVNF
BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

ACCESS Newswire 2 months ago

BOVNF
BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response ...

ACCESS Newswire 2 months ago

BOVNF
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and ...

ACCESS Newswire 2 months ago

BOVNF
BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in ...

ACCESS Newswire 3 months ago

BOVNF
BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for ...

ACCESS Newswire 3 months ago

BOVNF
Exploring High Growth Tech Stocks This November 2024

As global markets show resilience with major U.S. indexes approaching record highs and smaller-cap indexes outperforming, investor sentiment remains cautiously optimistic amid geopolitical tensions and economic uncertainties. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong fundamentals, innovative capabilities, and adaptability to evolving market conditions.

Simply Wall St. 4 months ago

BOVNF
BioInvent International AB: Interim Report January-September 2024

LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased ...

ACCESS Newswire 4 months ago

BOVNF
Invitation to Presentation of BioInvent’s Interim Report January - September 2024

LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2024 ...

ACCESS Newswire 5 months ago

BOVNF
High Growth Tech Stocks In Sweden For October 2024

As the European Central Bank's recent rate cuts fuel optimism for further monetary easing, Sweden's tech sector remains a focal point for investors seeking high growth opportunities amidst a broader positive market sentiment. In this dynamic environment, identifying stocks with strong fundamentals and innovative capabilities can be key to capitalizing on potential growth in the Swedish tech landscape.

Simply Wall St. 5 months ago

BOVNF

STRYF

BTRCF
High Growth Tech Stocks In Sweden To Watch Now

As global markets react to the Federal Reserve's recent rate cut, smaller-cap indices have shown promising performance despite remaining below previous peaks. This environment of monetary easing and economic optimism provides a fertile ground for high-growth tech stocks in Sweden, making it an opportune time to explore potential investments in this sector. Identifying strong candidates often involves looking at companies with robust innovation pipelines, solid financial health, and the...

Simply Wall St. 6 months ago

BOVNF

STRYF

BTRCF
BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV) Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily ...

ACCESS Newswire 6 months ago

BOVNF
BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place LUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent ...

ACCESS Newswire 6 months ago

BOVNF
BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part ...

ACCESS Newswire 6 months ago

BOVNF
BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) ...

ACCESS Newswire 6 months ago

BOVNF

Performance Overview

Return	BINV.ST	OMX Stockholm 30 Index (^OMX)
YTD	-26.49%	-2.93%
1-Year	+59.17%	-4.11%
3-Year	-38.28%	+13.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioInvent International AB (publ) (BINV.ST)

BioInvent to Participate in Upcoming Investor Conferences

Notice to Annual General Meeting in BioInvent International AB

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

BioInvent International AB: Year-End Report January 1 - December 31, 2024

Invitation to Presentation of BioInvent's Year-end Report 2024

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

Exploring High Growth Tech Stocks This November 2024

BioInvent International AB: Interim Report January-September 2024

Invitation to Presentation of BioInvent’s Interim Report January - September 2024

High Growth Tech Stocks In Sweden For October 2024

High Growth Tech Stocks In Sweden To Watch Now

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

Performance Overview